CONFERENCE COVERAGE SERIES
Alzheimer's Disease Research Summit 2012: Path to Treatment and Prevention
Natcher Auditorium, National Institutes of Health, Bethesda, Maryland, U.S.A.
14 – 15 May 2012
At the Alzheimer's Disease Research Summit 2012, held 14-15 May 2012 at the National Institutes of Health, speakers cited the Dominantly Inherited Alzheimer Network (DIAN) as an example of the kind of integrated observational and treatment initiative that advances the field.
DIAN Grows, Gets Ready for Therapeutic Trials
The Dominantly Inherited Alzheimer Network Pharma Consortium met in Washington, D.C., to exchange the latest information on DIAN’s preparation for therapeutic trials...
DIAN: What Sayeth the Regulator? Q&A With Rusty Katz
When the DIAN convened its Pharma Consortium, its scientists intended to brief the Food and Drug Administration on how far DIAN’s work has advanced to date...
NIH Director Announces $100M Prevention Trial of Genentech Antibody
Francis Collins announced that $16 million of federal funds would go toward the first-ever therapeutic prevention trial in cognitively healthy people...
Q&A With Ryan Watts, Genentech Lead Scientist on API Trial
Ryan Watts of Genentech is the founding research scientist on the clinical trial collaboration with the Alzheimer’s Prevention Initiative...